Brind.
  1. FDA approved Lytenava, an ophthalmic version of bevacizumab, for macular degeneration, with Medicare payment determining practice switch.

FDA approval is expected to trigger Medicare reimbursement step-up, while UnitedHealth Group covers the test ahead of guidelines.

1 report, 1 independent Updated Jul 31
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

FDA approval is expected to trigger Medicare reimbursement step-up, while UnitedHealth Group covers the test ahead of guidelines.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. Milestone Scientific is utilizing First Coast for reimbursement coverage and has successfully received Medicare reimbursement for its CompuFlo product.Sub-event
  2. FDA approval expected to trigger Medicare reimbursement step-up, with UHG covering the test early.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped